All News

Over the next 20 years, the number of new cancer cases diagnosed annually in the United States will increase by 45%, from 1.6 million in 2010 to 2.3 million in 2030, with a dramatic spike in incidence predicted in the elderly and minority populations, according to research from the University of Texas M.D. Anderson Cancer Center, Houston.

An investigational drug called MDV3100 has shown significant promise in lowering PSA levels in men with advanced prostate cancer who have no other option for cure.

Large numbers of physician extenders (PEs)?physician assistants and nurse practitioners?have been hired by general surgery residency programs during the last 5 years to bolster the resident education experience, and these professionals continue to be in demand, according to a recent study.

Prompted by reports of serious adverse events, the FDA announced that safety label changes, including a boxed warning and a Risk Evaluation and Mitigation Strategy, are necessary for all botulinum toxin products.

Nephron-sparing treatments, including partial nephrectomy, thermal ablation, and active surveillance, minimize risk of chronic kidney disease and cardiovascular disease and are viable options for patients with early-stage kidney tumors, according to a new clinical guideline issued by AUA.

360 Network

Results of a population-based, case-control study suggest there may be an association between marijuana use and the occurrence of testicular germ cell tumors (TGCTs), researchers from the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, reported.

President Obama's 2010 budget proposal, with its $630 billion down payment on health care reform over the next decade, appears to contain significant good news for urologists, but never has it been more true: the devil is in the details.

A study presented at the 2006 AUA annual meeting linked abuse and interstitial cystitis, raised a storm of controversy, and prompted more studies that confirmed higher rates of abuse in women with IC or lower urinary tract symptoms than in controls. But have those studies answered the question?

For this article, we interviewed Sundie Hallen, a senior trainer at McGrath Communications Group (www.mcgrathcg.com), who provides 10 tips for giving an effective Internet presentation.

Some urology practices have become complacent about managed care contracts, assuming there's not much they can do about them. But if it's costing more money to see a patient than you are getting paid, it's time to renegotiate or consider unloading the payer.

Classifying market movements is easy in hindsight, but how do you know which type of market we are heading into before it happens? The answer is that no one can predict market movements with any consistency.

In reviewing the data for multiple urology practices, the PRS Urology Data Initiative has shown that correctly billing for urodynamics has provided an immediate increase in income without adding new patients.

While you're making plans for the 2009 AUA annual meeting (April 25-30), be sure to pencil in some time to savor the wealth of recreational, cultural, entertainment, and dining opportunities offered in this west coast (of Lake Michigan) city.

"I don't subscribe to the theory that reps who come to our office have a tremendous impact on what we do anyway."

Products and services from manufacturers who are exhibiting at the American Urological Association meeting in Chicago.

Drugs and devices in the pipeline

In laboratories and surgical suites, urologists at Johns Hopkins University, Baltimore, are breaking new ground in prostate cancer research as well as setting improved quality standards of care.

Experienced clinicians, a broad range of treatment options, extensive and well-funded research, a large and comprehensive patient database, and a strong emphasis on collaboration make the Mayo Clinic's department of urology a Clinical Center of Excellence for the treatment of prostate cancer.

The Memorial Sloan-Kettering Cancer Center Sidney Kimmel Center for Prostate and Urologic Cancers is striving to defeat metastatic prostate cancer through aggressive efforts in prevention, detection, diagnosis, research, and treatment.

Cleveland Clinic has a history of pioneering innovation and leading-edge research in urology. Prostate cancer is no exception.